4ocr - Revision history

OCA at 17:09, 20 September 2023

2023-09-20T17:09:44Z

← Older revision		Revision as of 17:09, 20 September 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OCR FirstGlance]. <br>		<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OCR FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.895Å</td></tr>
			<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [https://pdbe.org/4ocr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [https://www.ebi.ac.uk/pdbsum/4ocr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ocr ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [https://pdbe.org/4ocr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [https://www.ebi.ac.uk/pdbsum/4ocr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ocr ProSAT]</span></td></tr>
	</table>		</table>

OCA at 07:17, 25 January 2023

2023-01-25T07:17:12Z

← Older revision		Revision as of 07:17, 25 January 2023
Line 3:		Line 3:
	<StructureSection load='4ocr' size='340' side='right'caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>		<StructureSection load='4ocr' size='340' side='right'caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4OCR FirstGlance]. <br>		<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OCR FirstGlance]. <br>
	</td></tr><tr id='~~NonStdRes~~'><td class="sblockLbl"><b>[[~~Non-Standard_Residue~~\|~~NonStd Res~~:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene>~~</td></tr>~~		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ocs\|4ocs]], [[4ocw\|4ocw]], [[4od1\|4od1]], [[4od3\|4od3]], [[4odh\|4odh]], [[4org\|4org]]~~</td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [https://pdbe.org/4ocr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [https://www.ebi.ac.uk/pdbsum/4ocr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ocr ProSAT]</span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [~~http~~://pdbe.org/4ocr PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4ocr PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4ocr ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 21:		Line 20:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Human~~]]		[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Doria-Rose~~, N A~~]]		[[Category: Doria-Rose NA]]
	[[Category: Gorman, J]]		[[Category: Gorman J]]
	[[Category: Kwong~~, P D~~]]		[[Category: Kwong PD]]
	[[Category: Mascola~~, J R~~]]		[[Category: Mascola JR]]
	[[Category: Moore~~, P L~~]]		[[Category: Moore PL]]
	[[Category: Morris, L]]		[[Category: Morris L]]
	[[Category: Schramm~~, C A~~]]		[[Category: Schramm CA]]
	[[Category: Shapiro, L]]		[[Category: Shapiro L]]
	~~[[Category: Cap256]]~~
	~~[[Category: Fab]]~~
	~~[[Category: Hiv-1]]~~
	~~[[Category: Immune system]]~~
	~~[[Category: V1v2]]~~
	~~[[Category: Vrc26~~]]

OCA at 08:51, 10 April 2019

2019-04-10T08:51:26Z

← Older revision		Revision as of 08:51, 10 April 2019
Line 1:		Line 1:

	==Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody==		==Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody==
	<StructureSection load='4ocr' size='340' side='right' caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>		<StructureSection load='4ocr' size='340' side='right'caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OCR FirstGlance]. <br>		<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OCR FirstGlance]. <br>
Line 22:		Line 22:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
			[[Category: Large Structures]]
	[[Category: Doria-Rose, N A]]		[[Category: Doria-Rose, N A]]
	[[Category: Gorman, J]]		[[Category: Gorman, J]]

OCA at 07:51, 11 August 2016

2016-08-11T07:51:08Z

← Older revision		Revision as of 07:51, 11 August 2016
Line 1:		Line 1:

	==Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody==		==Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody==
	<StructureSection load='4ocr' size='340' side='right' caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>		<StructureSection load='4ocr' size='340' side='right' caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>		</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ocs\|4ocs]], [[4ocw\|4ocw]], [[4od1\|4od1]], [[4od3\|4od3]], [[4odh\|4odh]], [[4org\|4org]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ocs\|4ocs]], [[4ocw\|4ocw]], [[4od1\|4od1]], [[4od3\|4od3]], [[4odh\|4odh]], [[4org\|4org]]</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [http://www.ebi.ac.uk/pdbsum/4ocr PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [http://pdbe.org/4ocr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [http://www.ebi.ac.uk/pdbsum/4ocr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4ocr ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 15:		Line 16:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
			<div class="pdbe-citations 4ocr" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 09:00, 5 January 2015

2015-01-05T09:00:42Z

← Older revision		Revision as of 09:00, 5 January 2015
Line 2:		Line 2:
	<StructureSection load='4ocr' size='340' side='right' caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>		<StructureSection load='4ocr' size='340' side='right' caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. <br>		<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OCR FirstGlance]. <br>
	</td></tr><tr><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>		</td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
	<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ocs\|4ocs]], [[4ocw\|4ocw]], [[4od1\|4od1]], [[4od3\|4od3]], [[4odh\|4odh]], [[4org\|4org]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ocs\|4ocs]], [[4ocw\|4ocw]], [[4od1\|4od1]], [[4od3\|4od3]], [[4odh\|4odh]], [[4org\|4org]]</td></tr>
	<tr~~><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class~~='~~plainlinks~~'~~>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span></td></tr>~~		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [http://www.ebi.ac.uk/pdbsum/4ocr PDBsum]</span></td></tr>
	~~<tr~~><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [http://www.ebi.ac.uk/pdbsum/4ocr PDBsum]</span></td></tr>		</table>
	<table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 14:		Line 13:
	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.,Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR Nature. 2014 Mar 2. doi: 10.1038/nature13036. PMID:24590074<ref>PMID:24590074</ref>		Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.,Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR Nature. 2014 Mar 2. doi: 10.1038/nature13036. PMID:24590074<ref>PMID:24590074</ref>

	From ~~MEDLINEÂ®~~/~~PubMedÂ®~~, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
	== References ==		== References ==
Line 21:		Line 20:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
	[[Category: Doria-Rose, N A.]]		[[Category: Doria-Rose, N A]]
	[[Category: Gorman, J.]]		[[Category: Gorman, J]]
	[[Category: Kwong, P D.]]		[[Category: Kwong, P D]]
	[[Category: Mascola, J R.]]		[[Category: Mascola, J R]]
	[[Category: Moore, P L.]]		[[Category: Moore, P L]]
	[[Category: Morris, L.]]		[[Category: Morris, L]]
	[[Category: Schramm, C A.]]		[[Category: Schramm, C A]]
	[[Category: Shapiro, L.]]		[[Category: Shapiro, L]]
	[[Category: Cap256]]		[[Category: Cap256]]
	[[Category: Fab]]		[[Category: Fab]]

OCA at 06:57, 14 May 2014

2014-05-14T06:57:50Z

← Older revision		Revision as of 06:57, 14 May 2014
Line 1:		Line 1:
	~~{{STRUCTURE_4ocr\| PDB=4ocr \| SCENE= }}~~		==Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody==
	===Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody===		<StructureSection load='4ocr' size='340' side='right' caption='[[4ocr]], [[Resolution\|resolution]] 1.90Å' scene=''>
	~~{{ABSTRACT_PUBMED_24590074}}~~		== Structural highlights ==
			<table><tr><td colspan='2'>[[4ocr]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA]. <br>
			</td></tr><tr><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=TYS:O-SULFO-L-TYROSINE'>TYS</scene></td></tr>
			<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4ocs\|4ocs]], [[4ocw\|4ocw]], [[4od1\|4od1]], [[4od3\|4od3]], [[4odh\|4odh]], [[4org\|4org]]</td></tr>
			<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span></td></tr>
			<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ocr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ocr OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ocr RCSB], [http://www.ebi.ac.uk/pdbsum/4ocr PDBsum]</span></td></tr>
			<table>
			<div style="background-color:#fffaf0;">
			== Publication Abstract from PubMed ==
			Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the developmental pathway by which such antibodies are generated and acquire the requisite molecular characteristics for neutralization. Twelve somatically related neutralizing antibodies (CAP256-VRC26.01-12) were isolated from donor CAP256 (from the Centre for the AIDS Programme of Research in South Africa (CAPRISA)); each antibody contained the protruding tyrosine-sulphated, anionic antigen-binding loop (complementarity-determining region (CDR) H3) characteristic of this category of antibodies. Their unmutated ancestor emerged between weeks 30-38 post-infection with a 35-residue CDR H3, and neutralized the virus that superinfected this individual 15 weeks after initial infection. Improved neutralization breadth and potency occurred by week 59 with modest affinity maturation, and was preceded by extensive diversification of the virus population. HIV-1 V1V2-directed neutralizing antibodies can thus develop relatively rapidly through initial selection of B cells with a long CDR H3, and limited subsequent somatic hypermutation. These data provide important insights relevant to HIV-1 vaccine development.

	~~==About this Structure==~~		Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.,Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, Nisc Comparative Sequencing, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR Nature. 2014 Mar 2. doi: 10.1038/nature13036. PMID:24590074<ref>PMID:24590074</ref>
	~~[[4ocr]] is a~~ 2 ~~chain structure~~. ~~Full crystallographic information is available from [http~~:/~~/oca~~.~~weizmann.ac.il~~/~~oca-bin/ocashort?id=4OCR OCA].~~

	==~~Reference~~==		From MEDLINEÂ®/PubMedÂ®, a database of the U.S. National Library of Medicine.<br>
	~~<ref group="xtra">PMID:024590074</ref>~~<references ~~group="xtra"~~/><~~references~~/>		</div>
			== References ==
			<references/>
			__TOC__
			</StructureSection>
			[[Category: Human]]
	[[Category: Doria-Rose, N A.]]		[[Category: Doria-Rose, N A.]]
	[[Category: Gorman, J.]]		[[Category: Gorman, J.]]

OCA at 07:51, 2 April 2014

2014-04-02T07:51:30Z

← Older revision		Revision as of 07:51, 2 April 2014
Line 1:		Line 1:
	{{STRUCTURE_4ocr\| PDB=4ocr \| SCENE= }}		{{STRUCTURE_4ocr\| PDB=4ocr \| SCENE= }}
	===Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody===		===Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody===
			{{ABSTRACT_PUBMED_24590074}}

	==About this Structure==		==About this Structure==
	[[4ocr]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA].		[[4ocr]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA].

			==Reference==
			<ref group="xtra">PMID:024590074</ref><references group="xtra"/><references/>
	[[Category: Doria-Rose, N A.]]		[[Category: Doria-Rose, N A.]]
	[[Category: Gorman, J.]]		[[Category: Gorman, J.]]

OCA at 18:27, 3 March 2014

2014-03-03T18:27:44Z

← Older revision		Revision as of 18:27, 3 March 2014
Line 1:		Line 1:
	~~'''Unreleased~~ structure~~'''~~		{{STRUCTURE_4ocr\| PDB=4ocr \| SCENE= }}
			===Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody===

	~~The entry~~ 4ocr is ~~ON HOLD until Paper Publication~~		==About this Structure==
			[[4ocr]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OCR OCA].
	~~Authors~~: ~~Gorman, J.,~~ Doria-Rose, N.A., ~~Schramm, C.A~~.~~, Moore~~, P.~~L.,~~ Mascola, J.R., ~~Shapiro,~~ L., Morris, L., ~~Kwong~~, ~~P.D~~.		[[Category: Doria-Rose, N A.]]
			[[Category: Gorman, J.]]
	~~Description~~: ~~Crystal structure of human~~ Fab ~~CAP256-VRC26.01, a potent V1V2-directed HIV~~-1 ~~neutralizing antibody~~		[[Category: Kwong, P D.]]
			[[Category: Mascola, J R.]]
			[[Category: Moore, P L.]]
			[[Category: Morris, L.]]
			[[Category: Schramm, C A.]]
			[[Category: Shapiro, L.]]
			[[Category: Cap256]]
			[[Category: Fab]]
			[[Category: Hiv-1]]
			[[Category: Immune system]]
			[[Category: V1v2]]
			[[Category: Vrc26]]

OCA at 04:50, 13 February 2014

2014-02-13T04:50:12Z

← Older revision		Revision as of 04:50, 13 February 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 4ocr is ON HOLD		The entry 4ocr is ON HOLD until Paper Publication

	Authors: Gorman, J., Doria-Rose, N.A., Schramm, C.A., Moore, P.L., Mascola, J.R., Shapiro, L., Morris, L., Kwong, P.D.		Authors: Gorman, J., Doria-Rose, N.A., Schramm, C.A., Moore, P.L., Mascola, J.R., Shapiro, L., Morris, L., Kwong, P.D.

	Description: Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody		Description: Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody

OCA at 06:47, 22 January 2014

2014-01-22T06:47:07Z

← Older revision		Revision as of 06:47, 22 January 2014
Line 3:		Line 3:
	The entry 4ocr is ON HOLD		The entry 4ocr is ON HOLD

	Authors: Gorman, J, Doria-Rose, NA, Schramm, CA, Moore, PL, Mascola, JR, Shapiro, L, Morris, L, Kwong, PD		Authors: Gorman, J., Doria-Rose, N.A., Schramm, C.A., Moore, P.L., Mascola, J.R., Shapiro, L., Morris, L., Kwong, P.D.

	Description: Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody		Description: Crystal structure of human Fab CAP256-VRC26.01, a potent V1V2-directed HIV-1 neutralizing antibody